The Latest
-
Galapagos finds a new normal at biotech's biggest dealmaking event
Though the Belgian drug company is tied to a 10-year, $5 billion research pact with Gilead, its CEO says there's still some "wheeling and dealing" left to do.
-
SponsoredSeeing patterns in the cloud: Charting a digital strategy with Life Sciences solutions
Discover the pros and cons of different delivery models to help organizations chart the right course.
-
Neuroscience's decade, a biotech's 'crown jewel,' and Ionis gets selective
Roche, maker of the last decade's top cancer drugs, is betting that neuroscience R&D can make strides in the 2020s — an outlook that contrasts with research retreats by the pharma's peers.
-
BioNTech rescues cancer biotech Neon in bargain buyout
The all-stock deal, worth $67 million, valued Neon at a 86% discount to the cell therapy developer's IPO price of $16 per share.
-
Nationwide Children's, a gene therapy leader, launches manufacturing spinout
Andelyn Biosciences, named after two children treated with gene therapy at Nationwide, will operate as a for-profit subsidiary of the Ohio-based hospital.
UPDATED: Jan. 15, 2020 at 10:10 a.m. -
Nektar quickly drops opioid drug after FDA panel rejection
After a decade of research, the biotech said it will withdraw its application for oxycodegol and make no further investment in the drug.
-
BioMarin sets gene therapy sights beyond hemophilia
At the JPM conference, the biotech announced a manufacturing lift and a new trial start that affirm its ambitions in gene therapy go beyond its closely watched hemophilia A treatment.
-
Alexion's neuro bet, Rubius' trial troubles and biotech's gene therapy milestones
On the first day of the JPM conference, Alexion mapped out ambitious plans in neuroscience, while Rubius did its best to explain delays in testing its first drug.
-
Astellas swoops in for Adaptimmune deal a day after positive data
For $50 million, the Japanese pharma signed up for three programs in a deal that could net Adaptimmune hundreds of millions more if all goes to plan.
-
With UK partnership, Novartis plots ambitious plans for new heart drug
The Swiss pharma giant will work with U.K. health officials to run a primary prevention study of inclisiran, acquired last month via a $10 billion deal for The Medicines Co.
UPDATED: Jan. 14, 2020 at 7:54 p.m. -
Biogen finds $75M home for Pfizer Alzheimer's drug
Having stepped back from neuroscience research, Pfizer will sell off an early-stage therapy to Biogen, which has made the space its central focus.
-
A biotech startup launches with unusual goal: invent new drugs, and sell them for less
Founded by venture capitalist Alexis Borisy, EQRx will launch with $200 million in funding to prove out a vision as daunting as it is ambitious.
-
Incyte turns to German Morphosys to refresh cancer pipeline
A licensing deal for Morphosys' near-to-market lymphoma drug will pad a pipeline that was recently weakened by a surprising study setback for Incyte.
-
After a record-breaking year, pharma M&A forecast to stay strong in 2020
A quiet start to the J.P. Morgan Healthcare Conference, often viewed as a gauge of dealmaking interest, could spark some doubts, however.
-
Lilly to buy Dermira, challenging Sanofi and Regeneron's Dupixent
With the industry's first significant acquisition of 2020, Lilly is positioning itself to compete in the growing atopic dermatitis market.
-
5 biotech trends to follow in 2020
Enthusiasm for new drugs and burgeoning companies will collide with an election year spotlight.
-
Blueprint wins 1st FDA approval with targeted cancer drug
The Boston-area biotech advanced Ayvakit from initial human testing to regulatory approval in just four years, a rapid timeline reflective of the drug's gene-targeted profile.
-
Moderna, though early in development, prepares its vaccine for market
The vaccine just began mid-stage testing, but Moderna is already preparing for the next steps, which include a large Phase 3 study and hiring of sales associates.
-
Ultragenyx boosted by trial data for 2nd gene therapy
One analyst called the results, which sparked a 30% jump in Ultragenyx's stock price, better than expected. The biotech is now preparing a Phase 3 trial.
-
Solid cuts one-third of staff, goes all in on delayed gene therapy
Re-starting a halted muscular dystrophy trial is Solid's priority as it puts a second drug and an assistive device on the backburner.
-
Amag CEO to step down as troubled pharma looks to sell 2 drugs
Emerging from an activist investor fight, Amag announced a restructuring plan and 2020 sales estimates that fell short of Wall Street expectations.
-
AbbVie to house Allergan Botox business in separate unit
Allergan's eyecare and specialty drugs, however, will be folded into the existing AbbVie organization once its $63 billion acquisition is complete.
-
5 trends to watch at the FDA in 2020
With Stephen Hahn confirmed as commissioner, the regulator is better positioned to more firmly address political pressures and a rising tide of complex medicines.
-
US cancer death rate drops by most on record
Reductions in smoking and earlier cancer detection have driven death rates lower, but newer treatments could be playing a larger role, too.
-
Lilly looms over Blueprint as the biotech files targeted cancer drug
Positive results in certain lung cancer patients support Blueprint's decision to submit pralsetinib, a RET-inhibitng drug, for approval in the first quarter.
